Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

BACKGROUND: We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers. METHODS: The study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Res...

Descripción completa

Detalles Bibliográficos
Autores principales: Colen, Rivka R, Rolfo, Christian, Ak, Murat, Ayoub, Mira, Ahmed, Sara, Elshafeey, Nabil, Mamindla, Priyadarshini, Zinn, Pascal O, Ng, Chaan, Vikram, Raghu, Bakas, Spyridon, Peterson, Christine B, Rodon Ahnert, Jordi, Subbiah, Vivek, Karp, Daniel D, Stephen, Bettzy, Hajjar, Joud, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051405/
https://www.ncbi.nlm.nih.gov/pubmed/33849924
http://dx.doi.org/10.1136/jitc-2020-001752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051405/
https://www.ncbi.nlm.nih.gov/pubmed/33849924
http://dx.doi.org/10.1136/jitc-2020-001752

Ejemplares similares